contraindications to glp 1 agonists Table 5 from Glucagon-Like Peptide-1 (GLP-1) Receptor Drug Class Review Independent Nurse - GLP-1 and

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in vivo models of neurodegenerative diseases through modulating a variety of pathogenic mechanisms, including neuroinflammation, autophagy, mitochondrial dysfunction, and the abnormal phosphorylation of pathognomonic proteins

A lower, fixed dose for those who want a gentle, mindful, cosmetic approach rather than full dose weight loss

Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity.

Compare early results with Wegovy and Mounjaro.

Glucagon-like peptide (GLP)-1 receptor agonists are the cornerstone in the treatment of hyperglycemia in many people suffering from type 2 diabetes (T2D)